NEW YORK, Feb. 28, 2011 /PRNewswire/ -- NeoStem, Inc. (NYSE: NBS), an international biopharmaceutical company with operations in the U.S. and China, announced today that Dr. Robin Smith, the Company's Chairman and CEO, will present on Tuesday, March 1, 2011 at the Wall Street Analyst Forum 22nd Annual Analyst Conference. The Conference will be held at the University Club at 1 West 54th Street, New York, New York. Dr. Smith will present as part of Track 2: "Biotechnology and Specialty Pharmaceuticals" from 9:50 AM to 10:30 AM.
In recapping its recent highlights, the Company will review multiple accomplishments. In January 2011, the Company acquired Progenitor Cell Therapy, LLC ("PCT"), an internationally recognized cell therapy services and development company that, through its cGMP certified manufacturing facilities and team of professionals, facilitates the preclinical and clinical development and eventual commercialization of cellular therapies for clients in the United States and internationally. In November 2010, the Company raised $19 million from two concurrent offerings. These funds supported the closing of the PCT acquisition and are helping the Company in growing its revenue lines of businesses in the US and China. Also in 2010, NeoStem was named "Best Stem Cell Company, 2010" in The New Economy's Biotech Awards. Additionally, the Vatican's Pontifical Council has undertaken to commit $1 million to joint ventures with NeoStem and the Stem for Life Foundation, a not-for-profit entity NeoStem participated in founding, to expand research and raise awareness of adult stem cell therapies.
In 2010, the Company also began generating revenues from what it believes will be the beginning of a pipeline of stem cell-based regenerative medicine therapies, a key element of its growth strategy in both the United States and China, with a collaboration
|SOURCE NeoStem, Inc.|
Copyright©2010 PR Newswire.
All rights reserved